Qube Research & Technologies (QRT)
CTMX icon

Qube Research & Technologies (QRT)’s CytomX Therapeutics CTMX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.84M Sell
1,824,564
-425,019
-19% -$1.62M 0.01% 1476
2026
Q1 		$10.6M Buy
2,249,583
+1,188,455
+112% +$6.03M 0.01% 1246
2025
Q4 		$4.52M Buy
1,061,128
+938,628
+766% +$3.57M ﹤0.01% 1823
2025
Q3 		$391K Buy
+122,500
New +$276K ﹤0.01% 2771
2025
Q2 		– Sell
-54,808
Closed -$34.8K – 3601
2025
Q1 		$34.8K Sell
54,808
-300
-0.5% -$233 ﹤0.01% 3168
2024
Q4 		$56.8K Hold
55,108
– – ﹤0.01% 3083
2024
Q3 		$65K Buy
55,108
+500
+0.9% +$635 ﹤0.01% 2814
2024
Q2 		$66.6K Sell
54,608
-78,591
-59% -$156K ﹤0.01% 2681
2024
Q1 		$290K Buy
133,199
+132,940
+51,328% +$245K ﹤0.01% 2837
2023
Q4 		$401 Hold
259
– – ﹤0.01% 3932
2023
Q3 		$334 Buy
+259
New +$408 ﹤0.01% 3710
2023
Q2 		– Sell
-13,050
Closed -$19.7K – 2487
2023
Q1 		$19.7K Sell
13,050
-43,231
-77% -$97.7K ﹤0.01% 2313
2022
Q4 		$90K Buy
56,281
+5,695
+11% +$8.43K ﹤0.01% 2028
2022
Q3 		$73K Sell
50,586
-5,260
-9% -$8.1K ﹤0.01% 2058
2022
Q2 		$102K Buy
+55,846
New +$107K ﹤0.01% 1945
2021
Q3 		– Sell
-18,101
Closed -$115K – 2301
2021
Q2 		$115K Buy
+18,101
New +$141K ﹤0.01% 1923

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CTMX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its CytomX Therapeutics (CTMX) stake by 19% in Q2 2026, selling an estimated $1.62M and leaving 1,824,564 shares worth $6.84M. The position accounts for 0.01% of the portfolio, ranked #1476.

Qube Research & Technologies (QRT) first reported a position in CTMX in Q2 2021 and has held it in 16 quarters since. The position peaked at $10.6M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Qube Research & Technologies (QRT) held 1,824,564 shares of CytomX Therapeutics worth $6.84M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 425,019 CytomX Therapeutics shares in Q2 2026, an estimated $1.62M.
  • CytomX Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1476 holding.
  • Qube Research & Technologies (QRT) first reported a position in CytomX Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • Qube Research & Technologies (QRT)'s CytomX Therapeutics position peaked at $10.6M in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.